Thrombus Embolisation: Prevention is Better than Cure. by Choudry, FA et al.
95©  R A D C L I F F E  C A R D I O L O G Y  2 0 1 9
Coronary
Access at: www.ICRjournal.com
Over the last few decades, primary percutaneous coronary intervention 
(PCI) has revolutionised the treatment of ST-elevation myocardial 
infarction (STEMI) with rapid recanalisation of the infarct-related 
epicardial vessel, resulting in smaller infarct size and a substantial 
reduction in adverse clinical endpoints.1,2 However, suboptimal 
myocardial reperfusion is documented to occur in a relatively large 
proportion of patients undergoing primary PCI for STEMI, despite 
optimal restoration of epicardial flow, with unfavourable short- and 
long-term outcomes.3 STEMI patients are at particularly high risk 
of thrombus embolisation due to elevated thrombotic burden and 
prothrombotic milieu.4 Thrombus embolisation, either spontaneously 
or as a consequence of instrumentation, is associated with reduced 
levels of procedural success. While this is most commonly related to 
embolisation into the distal coronary tree, it also includes retrograde 
embolisation either into non-culprit vessels or systemic emboli, which 
could further complicate primary PCI.
Distal embolisation can lead to re-occlusion of the culprit vessel or 
its downstream branches and is a major contributor to slow and no 
re-flow by occlusion of distal microvasculature, leading to ongoing 
ischaemia despite a patent epicardial artery. Thereby, evidence of distal 
embolisation is quantified by thrombolysis in MI (TIMI) flow, myocardial 
blush grade and ST segment resolution. While angiographic signs of 
distal embolisation occur in 6–18% of cases of primary PCI in STEMI,5–11 
the true incidence may be much higher, demonstrated by retrieval of 
visible debris in up to 73% patients in studies such as the Enhanced 
Myocardial Efficacy and Recovery by Aspiration of Liberated Debris 
(EMERALD) trial.12 
Thrombus embolisation is associated with adverse procedural results 
and a greater frequency of adverse outcomes, including larger infarct 
size, reduced left ventricular ejection fraction, larger enzyme rises and 
increased rates of recurrent MI and mortality.5,6,13 A high thrombus 
burden has been associated with incidence of distal embolisation 
and in itself is associated with PCI failure and adverse outcome in 
STEMI.14–16 Due to the prognostic implication of thrombus embolisation, 
management of lesions with high thrombotic burden remains a 
challenge in the setting of primary PCI for STEMI.
Case
A 49-year-old man presented with a history of chest pain and 
worsening breathlessness over the previous 3 days. He had a history 
of hypertension and smoking. On arrival he had on-going chest 
pain and was in mild pulmonary oedema. He was Kilip class II with 
a systolic blood pressure of 120 mmHg. His ECG showed a late 
presenting anterior STEMI with Q waves and a bedside echocardiogram 
demonstrated moderate to severely impaired LV function with anterior 
wall hypokinesia. A coronary angiogram demonstrated a chronic 
occlusion of the right coronary artery with an ostial occlusion of the 
left anterior descending (LAD) artery (Figure 1A). 
A standard workhorse wire was taken to the distal LAD with no 
restoration of flow. A 2.5 × 15 mm balloon was inflated at the site of 
occlusion (Figure 1B). The next image showed retrograde thrombus 
embolisation into a large obtuse marginal branch (Figure 1C). This was 
accompanied by a drop in blood pressure requiring IV metaraminol 
and rapid deterioration to pulseless electrical activity (PEA) arrest. 
Cardiopulmonary resuscitation was initiated, an AutoPulse® device 
applied, and the patient was intubated. A second wire was passed 
to the circumflex vessel and after predilatation a 3.0 × 28 mm drug-
eluting stent (DES) was deployed with a further 3.0 × 38 mm DES 
deployed in the LAD. Despite TIMI 3 flow in both vessels (Figure 1D), 
there was no return of spontaneous circulation and resuscitation was 
discontinued after 38 cycles of CPR.
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This case demonstrates retrograde thrombus embolisation into a non-
culprit vessel with a large amount of myocardium at risk due to chronic 
occlusion of the right coronary artery. To our knowledge, there are 
only two other published case reports in the literature. However, the 
outcomes are poor. This case highlights some technical considerations 
hat could have been considered, including passage of a second wire to 
the circumflex artery, thrombus aspiration upfront (with deep intubation 
of the guide catheter), use of glycoprotein (GP) IIb/IIIa inhibitors, and 
supportive measures, such as use of mechanical support either upfront 
due to the large area of myocardium at risk or at the point of thrombus 
embolisation; however, these can often be overlooked with the need 
for rapid restoration of TIMI 3 flow in the culprit vessel.
Thrombus embolisation, both distal and retrograde, is associated with 
increased morbidity and mortality in primary PCI and its management 
is still debated. Here we review current data for pharmacological 
and interventional strategies to prevent thrombus embolisation and 
suggest an optimal therapeutic strategy in the setting of large 
thrombus burden in primary PCI.
Angiographic Predictors of Thrombus 
Embolisation in Primary PCI
The main predictor of embolisation is thrombus burden. Thrombus 
burden may be classified angiographically using the TIMI thrombus 
grade in Table 1.17 Since there is a high incidence of coronary occlusion 
in STEMI and large thrombus burden, in this setting thrombus grade 5 
is reclassified after wire crossing and balloon passage/inflation.14 Other 
predictors of embolisation include thrombus composition, TIMI flow, 
lesion length and large vessel diameter.5–7,18 The anatomical risk of 
embolisation should also be assessed before deciding on therapeutic 
strategy. This allows for adjunctive therapies, such as mechanical 
support (intra-aortic balloon pump, Impella [Abiomed], extracoroporeal 
membrane oxygenation) to be considered where large areas of 
myocardium are at risk or if large thrombus is located close to an 
important bifurcation; protecting both branches with wires may help 
to prevent occlusion and facilitate treatment in the event of thrombus 
embolisation. Assessment of thrombus burden and composition, and 
anatomical risk of embolisation in patients with STEMI undergoing 
primary PCI may optimise percutaneous treatment of these highly 
thrombotic lesions, guiding utilisation of pharmacological agents or 
interventional strategies, to reduce thrombus burden and improve 
both epicardial and myocardial perfusion.
Pharmacological Strategies in Prevention of 
Thrombus Embolisation
P2Y12 Inhibitors
All STEMI guidelines have recommended early upstream administration 
of oral P2Y12 inhibitors or at the latest at the time of PCI given 
their delay in onset of action.19 However, this is not evidenced by 
randomised trials. Upstream oral antiplatelet absorption may not 
always be achievable in situations of intubated patients or in patients 
with delayed absorption (e.g. morphine) or if associated vomiting. 
The only evidence currently available is from the 30 Day Study to 
Evaluate Efficacy and Safety of Pre-hospital vs In-hospital Initiation 
of Ticagrelor Therapy in STEMI Patients Planned for PCI (ATLANTIC) 
trial, which compared the upstream prehospital and periprocedural 
administration of ticagrelor in 1,862 STEMI patients with a mean 
time difference of 31 minutes. There was no difference in the rates 
of ST segment resolution or TIMI 3 flow between the two groups.20 
Given that less than 50% patients with prasugrel and ticgarelor have 
optimal platelet inhibition at 2 hours and the problems with gastric 
absorption in specific patient groups anecdotally, these cases may be 
covered with GPIIb/IIIa inhibition.21 Recent guidelines recommend that 
cangrelor may be considered in patients who have not received P2Y12 
inhibitors (IIb/A).19 Cangrelor is administered intravenously and has a 
faster onset of action. While there are no specific randomised trials in 
STEMI, pooled analysis from STEMI patients included in the Clinical Trial 
to Demonstrate the Efficacy of Cangrelor in PCI (CHAMPION PCI) and 
Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in 
Subjects Who Require PCI (CHAMPION-PHOENIX) showed a significant 
reduction in stent thrombosis at 30 days.22
Glycoprotein Inhibitors
Despite some evidence to suggest that adjunctive administration of 
GPIIb/IIIa inhibitors in STEMI may reduce mortality and re-infarction23 
there is no evidence to suggest benefit over risk of bleeding with 
routine facilitated use of GPIIb/IIIa inhibitors in STEMI.24–28 Although initial 
non-randomised trials suggested benefit of localised intracoronary 
delivery of GPIIb/IIIa inhibitor over intravenous delivery in terms of 
TIMI flow and short-term mortality, no overall mortality benefit has 
been demonstrated.29 There also appears to be a signal for use of 
intracoronary GPIIb/IIIa use from theIntracoronary Abciximab and 
Aspiration Thrombectomy in Patients With Large Anterior MI (INFUSE-
AMI) trial where abciximab was delivered using the ClearWay™ (Atrium 
Medical) infusion catheter where there was a reduction in infarct size 
in the intracoronary arm compared with intravenous of 2.3%, but this 
did not reach significance.30 
However, the larger Abciximab IV Versus IC in ST-elevation MI (AIDA 
STEMI) trial (n=2065) did not show any reduction in clinical endpoints 
by intracoronary abciximab administration and this again was 
demonstrated in a more recent meta-analysis.31,32 Current guidelines 
suggest that while there is no evidence to recommend routine 
use of GP IIb/IIIa inhibitors, they may be considered in the event of 
Figure 1: Case of Thrombus Embolisation
A B
DC
A: Occlusion of ostial left anterior descending artery. B: 2.5 × 15 mm balloon inflation.  
C: Retrograde thrombus embolisation into obtuse marginal; D: Result of percutaneous 
coronary intervention.
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angiographic evidence of large thrombus, slow- or no-reflow, and other 
thrombotic complications. It is important to note that this strategy has 
not yet been tested in randomised trials.
Anticoagulant Therapy
While there has been no randomised trial assessing unfractionated 
intraprocedural heparin in primary PCI there is a substantial body of 
experience and its use is recommended in current guidance (I/C).19 
There have been some randomised trials evaluating bivalirudin in the 
setting of STEMI with a recent meta-analysis demonstrating no mortality 
advantage and concerns over excess rates of early stent thrombosis 
in the bivalirudin treated arms.25,33–37 Further, the most recent large 
randomised study on the impact of bivalirudin during primary PCI 
for STEMI, Bivalirudin versus Heparin in ST-Segment and Non-ST-
Segment Elevation MI in Patients on Modern Antiplatelet Therapy in the 
Swedish Web System for Enhancement and Development of Evidence-
based Care in Heart Disease Evaluated according to Recommended 
Therapies Registry (VALIDATE-SWEDEHEART) trial randomising 3,005 
patients with STEMI showed no benefit conferred by bivalirudin use 
in rates of myocardial infarction, bleeding and death at 180 days 
compared to unfractionated heparin.38 Therefore, current guidance has 
downgraded recommendation of bivalirudin use from I/B preferred to 
IIa/A (consider). Bivalirudin is also recommended in heparin-induced 
thrombocytopaenia.19
Intracoronary Thrombolysis
Early small studies of local delivery of fibrinolytics as an adjunct to 
primary PCI showed promising results with improvement in myocardial 
reperfusion and TIMI flow in the infarct-related artery, suggesting that 
this may be beneficial adjunctive treatment in STEMI patients at high 
risk of thrombus embolisation, without the known systemic adverse 
effects.39,40 The first randomised trial, Delivery of Thrombolytics Before 
Thrombectomy in Patients With ST-Segment Elevation Myocardial 
Infarction Undergoing primary Percutaneous Coronary Intervention 
[DISSOLUTION]), where 102 patients with STEMI and large thrombus 
burden were randomised to either intracoronary urokinase delivered 
by microcatheter or placebo prior to thrombectomy demonstrated 
increased rate of TIMI 3 flow, myocardial blush grade, ST segment 
resolution as well as improvement in 6-month major adverse cardiac 
events.41 However, the recently reported Trial of Low-dose Adjunctive 
alTeplase During prIMary PCI (T-TIME), which randomised 440 patients 
with STEMI to either placebo, 10 mg alteplase or 20 mg alteplase after 
the first device in primary PCI (37–42% use of thrombectomy), showed 
no difference in the primary endpoint of extent of microvascular 
obstruction on cardiac MRI at 2–7 days.42 There are currently two 
ongoing Phase III trials to evaluate intracoronary low-dose alteplase, 
the Adjunctive Low-dose tPA in Primary PCI for STEMI (STRIVE, 
NCT03335839) study, and tenecteplase, the Restoring Microcirculatory 
Perfusion in STEMI (RESTORE-MI; ACTRN12618000778280) trial.
Mechanical Strategies in Prevention of 
Thrombus Embolisation
Thrombectomy
Thrombectomy devices have been developed in an attempt to prevent 
thrombotic complications in STEMI by reducing thrombus burden 
and thereby enhancing the benefits of primary PCI. These have been 
evaluated for routine use in STEMI in some studies.
Mechanical devices include the AngioJet® (MEDRAD), X-SIZER® System 
(Covidien) and Rinspiration (eV3) that actively fragment and aspirate 
thrombus, and the TVAC® (Nipro) and Rescue (Boston Scientific) 
that aspirate thrombus only without fragmentation. Several trials 
using different mechanical devices have led to conflicting results. 
Both the AngioJet Rheolytic Thrombectomy In Patients Undergoing 
Primary Angioplasty for Acute MI (AIMI) trial randomising 480 STEMI 
patients to thrombectomy with Angiojet versus standard primary 
PCI and a second study randomising 215 patients to thrombectomy 
with the Rescue catheter versus standard primary PCI paradoxically 
demonstrated large infarct sizes in the treated arms.43,44 Conversely, 
the AngioJet Rheolytic Thrombectomy Before Direct Infarct Artery 
Stenting in Patients Undergoing Primary PCI for Acute MI (JETSTENT) 
trial where the Angiojet was tested in a cohort with large thrombus 
burden showed significant improvements in ST segment resolution, 
and 6-month major adverse cardiac event despite no difference in 
infarct size.45 A meta-analysis of mechanical thrombectomy in STEMI 
showed no improvement in reperfusion or mortality despite a benefit 
in ST segment resolution.46
Most of the current available thrombectomy data pertains to manual 
thrombus aspiration using the Export® Aspiration Catheter (Medtronic) 
or the Diver® (Invatec). These devices are simpler to use compared 
to mechanical devices. However, they are limited by the inability to 
aspirate large amounts of thrombus rendering them theoretically less 
effective in reducing thrombus load. 
Manual thrombectomy devices have shown benefits compared with 
standard primary PCI using surrogate endpoints, such as TIMI flow, 
ST segment resolution, myocardial blush grade, infarct size and LV 
function.47 However, evidence regarding clinical endpoints such as 
re-infarction, mortality and MACE as well as concerns regarding safety 
have meant that current guidance has downgraded the use of routine 
thrombectomy from recommended (IIa/B) to not recommended (III/A).19 
The Thrombus Aspiration during Percutaneous coronary intervention 
in Acute MI Study (TAPAS) trial, where more than 1,000 STEMI patients 
were randomised to either routine thrombus aspiration (Export 
Aspiration Catheter) or conventional primary PCI, showed significant 
improvement in myocardial blush grade and ST segment resolution as 
well as increased 1-year survival.9 
Table 1: Thrombolysis in Myocardial Infarction  
Thrombus Scale
Grade Description
0 No angiographic evidence of thrombus
1 Angiographic features suggestive of thrombus
 • decreased contrast density
 • haziness of contrast
 • irregular lesion contour
 • a smooth convex meniscus at the site of a total occlusion
 • suggestive, but not firmly diagnostic of thrombus
2 Definite thrombus presents in multiple angiographic projections 
 • marked irregular lesion contour with a significant filling defect
 • greatest dimension is <1/2 vessel diameter
3 Definite thrombus appears in multiple angiographic views
 • greatest dimension from >1/2 to <2 vessel diameters
4 Definite large size thrombus present
 • greatest dimension >2 vessel diameters
5 Definite complete thrombotic occlusion of a vessel
 •  a convex margin that stains with contrast, persisting for 
several cardiac cycles
ICR_Mathur_FINAL.indd   97 14/05/2019   22:08
98
Thrombus EmbolisationCoronary
I N T E R V E N T I O N A L  C A R D I O L O G Y  R E V I E W
However, recently, two large-scale randomised trials of manual 
powered to evaluate hard clinical endpoints comparing routine 
manual thrombus aspiration with standard primary PCI have definitely 
demonstrated no beneficial effect of routine thrombectomy.48,49 The 
Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction 
in Scandinavia (TASTE) trial recruited over 7,000 patients and showed 
no difference in mortality between the two groups at 30 days or 1 
year.48,50 The Trial of Routine Aspiration Thrombectomy With PCI Versus 
PCI Alone in Patients With STEMI (TOTAL) trial with over 10,000 patients 
corroborated this result with no difference in cardiovascular death, MI, 
cardiogenic shock, or heart failure at 1 year, despite improvements 
in surrogate markers of rate of distal embolisation and ST segment 
resolution.49,51 Importantly, TOTAL showed a clear safety signal with 
an increase in incidence of stroke at 1 year in the thrombectomy arm 
compared with primary PCI alone.52 The mechanism of this is presumed 
to be proximal or systemic embolisation of thrombus via the extraction 
of the device and it is therefore recommended that the guide be 
deeply engaged into the coronary ostium during thrombus aspiration 
and device removal as a preventative strategy; alternatively, a guide 
catheter extension may be used. 
A recent meta-analysis combined data from 18,306 patients from the 
TAPAS, TASTE and TOTAL trials showed overall no differences between 
the two treatment groups in terms of mortality at 30 days, or incidence 
of stroke.53 Subgroup analysis demonstrated that in patients with the 
highest thrombus burden defined by TIMI thrombus grade ≥3 there 
were fewer cardiovascular deaths as well; however, this group also had 
increased incidence of stroke/transient ischaemic attack; this could 
suggest that if systemic embolisation could be prevented then benefit 
could be seen in this high thrombus burden subgroup of patients.
Taken together, this would suggest that patients with a high thrombus 
burden benefit the most from thrombectomy by reducing the 
incidence of distal embolisation. Current guidelines have suggested 
that while routine thrombus aspiration is not recommended, it may be 
considered in specific cases where there is a high thrombus burden 
and risk of embolisation.19 Innovations in device technology should 
now focus on mitigating risk of systemic embolisation and stroke 
during thrombectomy. Further trials are required to evaluate the utility 
and benefit of thrombus aspiration in cohorts with large thrombus 
burden; however, this would require large patient numbers to be 
powered to detect differences in hard clinical outcomes.
Embolic Protection Devices
Embolic protection devices include both proximal and distal devices. 
Distal devices are either occlusive, such as the PercoSurge (Medtronic) 
whereby an occlusive balloon is inflated distal to the lesion with debris 
aspirated prior to deflation or filters such as the FilterWire EZ (Boston 
Scientific), which is a non-occlusive, filter-based distal protection 
device. While there is evidence to support embolic protection devices 
in the prevention of thrombus embolisation vein graft PCI, these 
have not been replicated in the setting of STEMI. Both the Exploring 
the MEchanism of Plaque Rupture in Acute Coronary Syndrome 
Using Coronary CT Angiography and computationaL Fluid Dynamic 
(EMERALD) trial and ASPiration of Liberated Debris in Acute MI with 
GUardWire Plus System (ASPARAGUS) trials comparing adjunctive 
PercoSurge to conventional primary PCI in 501 and 341 patients, 
respectively, demonstrated safety of the devices but failed to show 
benefit in terms of infarct size.12,54 These results were reflected in the 
PROspective Multicenter Imaging Study for Evaluation of chest pain 
(PROMISE) trial which randomised 200 patients with STEMI to the 
FilterWire EZ or conventional primary PCI.55 An analysis of all trials of 
distal protection devices involving 1,353 patients showed that while 
there was some benefit in terms of myocardial blush grade there was 
no improvement in 30-day mortality.56
The only studied proximal protection device is the Proxis Embolic 
Protection System (Velocimed) which theoretically confers complete 
protection from distal embolisation by deployment proximal to the 
lesion interrupting antegrade flow and therefore has the benefit of 
protecting all distal branches while thrombus is aspirated. The PRoximal 
Embolic Protection in Acute MI and Resolution of ST-Elevation trial, the 
only trial to date evaluating this device in STEMI, showed no benefit 
conferred in either surrogate or clinical outcomes.57 Considering the 
paucity of data for embolic protection devices, they have not been 
recommended in current practice guidelines.
Excimer Laser Coronary Atherectomy
Excimer laser coronary atherectomy (ELCA) is potentially effective 
in reducing the size of coronary thrombus by inducing shock waves 
that can separate thrombus from the vessel wall, dissolve clot by 
acoustic waves within the thrombus structure and vaporise pro-
coagulant mediators.58,59 Laser also has an inhibitory effect on platelet 
aggregation due to interaction with the 308-nm ultraviolet beam 
leading to ‘stunned platelet phenomenon’.60 Despite the theoretical 
potential, there are limited data to support its use in primary PCI. 
The Cohort of Acute Revascularization of Myocardial infarction with 
Excimer Laser (CARMEL) multicentre registry, enrolled 151 AMI patients, 
65% of whom had large thrombus burden in the culprit artery who 
gained most benefit.61 TIMI grade flow was significantly improved and 
there was a low rate of major adverse cardiac event (8.6%). Recently, 
another large registry (Utility of Laser for Transcatheter Atherectomy-
Multicenter Analysis around Naniwa [ULTRAMAN]) has reported on 
175 STEMI patients treated with ELCA, again showing similar TIMI 
flow improvement, a 92.8% success rate, and major adverse cardiac 
event rate of 3.3%.62 The only randomised trial reported to date is the 
Excimer Laser Versus Manual Thrombus Aspiration in Acute Myocardial 
Infarction (LASER-AMI) trial where 27 STEMI patients were randomised 
to adjunctive ELCA or conventional primary PCI demonstrating safety 
of the device and similar outcomes in terms of TIMI grade flow, and 
myocardial blush in both groups.63
Stenting Strategy
A direct stenting strategy reduces the incidence of distal embolism 
and no-reflow in cases of high thrombus burden by trapping thrombus 
behind the stent. It has been validated by several studies that have 
demonstrated superiority over angioplasty with predilatation and 
stenting. In Harmonizing Outcomes with Revascularization and Stents 
in Acute MI (HORIZON-AMI) trial, the reperfusion indices (ST resolution, 
TIMI 3 flow, and no-reflow incidence) were better and the 1-year 
mortality was lower with this technique.64 However, the anticipated 
benefits need to be balanced alongside possible risks with this 
technique, including problematic stent delivery, incomplete lesion 
preparation and inaccurate stent sizing secondary to poor visualisation 
and vasoconstriction.
In terms of stent choice in cases of large thrombus burden, the 
MGuard™ (InspireMD) and STENTYS™ (STENTYS SA) stents have recently 
been evaluated in randomised trials. The MGuard is a covered stent 
with a bare metal stent platform with a fine outer mesh with the aim 
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to trap thrombus without prolapse through stent struts and prevent 
thrombus embolisation. The MASTER I trial randomising 433 STEMI 
patients to either MGuard or conventional stenting demonstrated 
promising results with improvement in ST segment resolution and 
improved mortality at 1 year.65,66 However, the MASTER II trial, which 
aimed to recruit 1,114 patients, was terminated early due to a high rate 
of stent dislodgement. 
The STENTYS is a self-apposing and self-expanding nitinol stent with its 
design offering several benefits in thrombus management. First, as the 
maximal expansion diameters of each of the stent sizes is at least 1 mm 
greater than the balloon size, a smaller diameter may be chosen than 
that of the artery, enabling a gentler and atraumatic deployment which 
limits the direct mechanical fragmentation of the atherothrombotic 
material. Second, the tight mesh allows better retention of the 
thrombotic mass against the wall. Third, the risk of late malapposition 
is reduced as expansion may continue with the stent conforming to 
the shape of the vessel as vasodilatation and thrombus lysis occur. 
This stent has been evaluated in a series of studies (APPOSITION IV).67–70 
While use of this stent has not been studied in cases of large thrombus 
burden, APPOSITION IV randomised 152 STEMI patients to STENTYS or 
to conventional DES and reported a rate of malapposition at 4 months 
less with the STENTYS than with the comparator.70 Despite this, their 
clinical effectiveness in comparison to other stent designs still needs 
to be confirmed in large-scale, randomised clinical trials.
Deferred stenting implantation in primary PCI is also an option to 
reduce embolisation of thrombotic material in the presence of high 
thrombus burden once antegrade flow has been restored. This 
can allow 24–48 hours of intense antithrombotic therapy, including 
prolonged intravenous GPIIb/IIIa inhibition. Subsequent angiography 
frequently shows reduced thrombus burden such that PCI may be 
performed with a significantly lower risk of distal embolisation.71 
While the randomised Deferred Stenting Versus Immediate Stenting to 
Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial 
Infarction (DEFER-STEMI) trial showed significantly lower rates of 
no-reflow in a high risk population,72 the MIMI trials showed no 
difference in rate of microvascular obstruction seen on cardiac MRI 
between immediate invasive treatment compared with deferred PCI.73 
This signal was confirmed in the larger Deferred Versus Conventional 
Stent Implantation in Patients with ST-segment Elevation Myocardial 
Infarction (DANAMI 3-DEFER) study in which deferred stenting 48 
hours after the index procedure had no effect on a composite 
clinical outcome of mortality and revascularisation of non-culprit 
vessels. However, it did demonstrate a higher rate of target vessel 
revascularisation.74 On the basis of the available data, deferred stenting 
is not recommended in the current guidelines (III/A).19
Therapeutic Strategy for Prevention of 
Thrombus Embolisation in Primary PCI
There is conflicting evidence as to the ideal management strategy 
in cases of large thrombus burden in STEMI. Based on the evidence 
presented here we propose an interventional algorithm in these cases 
(Figure 2). For all cases, potent antiplatelet activity must be ensured 
to minimise the risk of thrombus expansion and new thrombus 
formation including consideration as to gastric absorption of oral 
aspirin/P2Y12 agents. If there is any doubt in this the patient may 
be covered with either IV cangrelor or GPIIb/IIIa inhibition upfront. 
Furthermore, anticoagulation should be maintained with either heparin 
or bivalirudin. Often wire crossing or balloon passage without inflation 
can restore flow. Assessment of thrombus burden may then be made 
using the TIMI thrombus grading.14 As thrombus grade increases more 
benefit may be yielded from administration of GP IIb/IIIa inhibition. 
Further, consideration should be given to anatomical risk of thrombus 
aspiration in terms of need for supportive measures such as mechanical 
support as well as protection of branches especially in ostial stenosis. 
If the TIMI thrombus grade is ≥3 as described as large thrombus 
burden,14 aspiration thrombectomy should be considered and multiple 
runs may be necessary (or excimer laser if available although this is 
based on limited evidence). Thrombus aspiration if performed should 
either be with deep guide catheter engagement or a guide catheter 
extension to decrease risk of retrograde embolisation. Moreover, 
suction should be maintained until the thrombectomy catheter is 
removed from the guide catheter. Thereafter, balloon angioplasty and 
stenting may be performed, although there may be benefit in the 
setting of large thrombus load for direct stenting and consideration of 
either the MGuard or STENTYS stents. If antegrade flow is restored and 
large thrombus burden remains without ongoing ischaemia one other 
option to consider in preventing thrombus embolisation would be to 
defer further intervention by 24–48 hours with intense antithrombotic 
therapy, including prolonged GPIIb/IIIa inhibition.
Conclusion
Large thrombus burden in STEMI can further complicate primary PCI 
due to spontaneous or mechanical embolisation, either distally or 
retrograde, into a non-culprit vessel or systemically. In the context of 
no proven recommendation in this setting, we discuss some adjunctive 
and preventative pharmacological and interventional strategies and 
propose a management algorithm in the primary PCI setting. 
Figure 2: Proposed Algorithm for Primary PCI in the 
Presence of Large Thrombus Burden
Wire passage
TG 0–2
Direct stent
Balloon/stent
No ischaemia/
TIMI ow 3
TG 3–5
Ischaemia/
TIMI ow <3
Thrombus aspiration
(or excimer laser)
Consider: GPIIb/IIIa 48 h/
deferred angiography ±PCI
Direct stent
Balloon/stent
Consider: Mguard/
STENTYS/embolic protection
GPIIb/IIIa inhibition
Consider risk of embolisation:
mechanical support/branch protection
Ensure adequate oral dual antiplatelets/IV cangrelor/IV GPIIb/IIIa
Ensure adequate anticoagulation during procedure
GP = glycoprotein; PCI = percutaneous coronary intervention; TG = thrombolysis in MI 
thrombus grade; TIMI = thrombolysis in MI.
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